March 4, 2021
Chikungunya antibody identified at VUMC moves forward
Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
By Bill Snyder